Doptelet cost-effective, avoids transfusions for CLD-related thrombocytopenia

Treatment with Doptelet was cost-effective for the treatment of thrombocytopenia in patients with chronic liver diseases compared with other treatment options, according to data presented at the American Society of Hematology meeting.The study compared Doptelet (avatrombopag, Dova Pharmaceuticals), an oral thrombopoietin receptor agonist approved by both the FDA and the European Medicines Agency (EMA) for treatment of thrombocytopenia in adults with CLD who are scheduled to undergo a procedure, with platelet transfusion and Mulpleta (lusutrombopag, Shinogi).“The results showed that theRead More

Share on facebook
Share on twitter
Share on linkedin